EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Balloon-Assisted Enteroscopy Assesses Endoscopic Remission and Mucosal Healing following Risankizumab Initiation in Crohn’s Disease

Shinya Yoshida, Atsushi Nishida, Yoshihiro Yokota, Takayuki Imai, Masashi Ohno, Takuji Iwashita

Inflammatory Intestinal Diseases · 07.07.2026 · 11 (1) · 325-336

DOI: 10.1159/000553291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 07.07.2026. Verfasst von Shinya Yoshida und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Shiga University of Medical Science, Otsu, Japan. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Endoscopic control of inflammation is a key treatment goal in Crohn’s disease. However, real-world endoscopic outcomes of risankizumab assessed by paired balloon-assisted enteroscopy (BAE) remain limited. We examined endoscopic outcomes at the visit closest to week 52 after risankizumab initiation using paired BAE.

Methods

We retrospectively studied adults with Crohn’s disease who initiated risankizumab. The primary analysis set comprised 42 patients who underwent BAE at baseline and at the visit closest to week 52. Endoscopic activity was quantified using the Simple Endoscopic Score for Crohn’s Disease (SES-CD). Endoscopic remission was defined as SES-CD ≤4 with a decrease of ≥2 points from baseline, and mucosal healing was defined as SES-CD ≤2.

Results

In the paired BAE cohort (n = 42), the median SES-CD improved from 9 at baseline to 2 at follow-up (p < 0.0001). At follow-up, 76.2% (32/42) achieved endoscopic remission and 52.4% (22/42) achieved mucosal healing. Endoscopic remission was more frequent in bio-naïve than bio-experienced patients (93.3% vs. 66.7%, p = 0.054), whereas mucosal healing rates were similar (53.3% vs. 51.9%, p = 0.92).

Conclusion

In this real-world Japanese cohort, risankizumab was associated with significant endoscopic improvement assessed by paired BAE at follow-up. Endoscopic remission and mucosal healing rates were high in the paired BAE cohort, particularly for endoscopic remission among bio-naïve patients.

Schlagwörter

Stichwörter der Autor:innen

Balloon-assisted enteroscopyCrohn’s diseaseEndoscopic remissionMucosal healingRisankizumab

Autor:innen und Institutionen

  • Department of Medicine, Shiga University of Medical Science, Otsu, Japan.

Zitieren

APA

Yoshida, S., Nishida, A., Yokota, Y., Imai, T., Ohno, M., & Iwashita, T. (2026). Balloon-Assisted Enteroscopy Assesses Endoscopic Remission and Mucosal Healing following Risankizumab Initiation in Crohn’s Disease. Inflammatory Intestinal Diseases, 11(1), 325-336. https://doi.org/10.1159/000553291

Vancouver

Yoshida S, Nishida A, Yokota Y, Imai T, Ohno M, Iwashita T. Balloon-Assisted Enteroscopy Assesses Endoscopic Remission and Mucosal Healing following Risankizumab Initiation in Crohn’s Disease. Inflammatory Intestinal Diseases. 2026;11(1):325-336. doi:10.1159/000553291

BibTeX
@article{Yoshida2026,
  author = {Yoshida, Shinya and Nishida, Atsushi and Yokota, Yoshihiro and Imai, Takayuki and Ohno, Masashi and Iwashita, Takuji},
  title = {Balloon-Assisted Enteroscopy Assesses Endoscopic Remission and Mucosal Healing following Risankizumab Initiation in Crohn’s Disease},
  journal = {Inflammatory Intestinal Diseases},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {325--336},
  doi = {10.1159/000553291}
}
Kostenlos starten →